317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision
The Readout Loud
00:00
Intro
This chapter explores critical developments in the biotech sector, including Medicare negotiations for drug prices and their implications for the industry. It also addresses the challenges biotech VC firms face in fundraising and highlights a merger between two AI drug startups, reflecting current trends in life sciences.
Transcript
Play full episode
